Press Releases

Date Title and Summary Additional Formats
Toggle Summary SCYNEXIS, Inc. to Present at the Canaccord Genuity Growth Conference
JERSEY CITY, N.J., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at the Canaccord Genuity Growth Conference at the InterContinental Boston on Thursday, August 11, 2016 at 2:00 p.m. ET.
View HTML
Toggle Summary SCYNEXIS Announces Interim Results from Phase 2 Study of Oral SCY-078 in Patients with Invasive Candidiasis
Oral Dose of SCY-078 That Achieves Target Exposure Identified SCY-078 Safe and Well-Tolerated Antifungal Clinical Activity of SCY-078 Further Confirmed JERSEY CITY, N.J., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced the results of an
View HTML
Toggle Summary SCYNEXIS, Inc. Announces Sale of Cyclophilin Inhibitor Assets to Cypralis Limited
JERSEY CITY, N.J., July 13, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that the Company has entered into an Asset Purchase agreement with UK-based Cypralis Limited, a life sciences company focused on the discovery of novel therapeutics based on
View HTML
Toggle Summary SCYNEXIS, Inc. to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference
JERSEY CITY, N.J., July 06, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at Cantor Fitzgerald's 2 nd Annual Healthcare Conference at Le Parker Meridien New York on Tuesday, July 12, 2016 at 9:00 a.m. ET.
View HTML
Toggle Summary SCYNEXIS Announces Pricing of $22.5 Million Public Offering of Common Stock and Warrants
JERSEY CITY, N.J., June 21, 2016 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq:SCYX) today announced the pricing of its underwritten public offering of 9,375,000 shares of its common stock and warrants to purchase 4,218,750 shares of its common stock. The shares and warrants are being sold at a public
View HTML
Toggle Summary SCYNEXIS Announces Launch of Public Offering of Common Stock and Warrants
JERSEY CITY, N.J., June 20, 2016 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that it has commenced an underwritten public offering of shares of its common stock and warrants to purchase shares of its common stock. The company expects to grant the underwriter a 30-day option to
View HTML
Toggle Summary SCYNEXIS Inc. Presents New Clinical and Non-Clinical Data Confirming the Potential of SCY-078 as a Novel Treatment for Life-threatening Fungal Infections
SCY-078 shown to be the first glucan synthase inhibitor with high oral bioavailability in humans Fungicidal activity of SCY-078 demonstrated against multiple Candida species, including difficult-to-treat strains SCY-078 progressing to next stages of clinical development in invasive candidiasis with
View HTML
Toggle Summary SCYNEXIS to Present Data from Lead Antifungal Drug Candidate SCY-078 at ASM Microbe 2016
JERSEY CITY, N.J., June 10, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) announced today that results of one Phase 1 study and one nonclinical study of the company's lead clinical drug candidate, SCY-078, will be presented in podium presentations at ASM Microbe
View HTML
Toggle Summary SCYNEXIS, Inc. Announces Positive Results in its Proof-of-Concept Phase 2 Study of SCY-078, the First Member of a Novel Class of Glucan Synthase Inhibitors
Confirmation of Clinically Relevant Antifungal Activity of SCY-078 in Patients with Candida Infections Company to Host a Conference Call Today at 5:00pm ET to Discuss Results JERSEY CITY, N.J., June 08, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc.
View HTML
Toggle Summary SCYNEXIS, Inc. Receives Orphan Drug Designation for SCY-078 for the Treatment of Invasive Candida Infections
JERSEY CITY, N.J., May 13, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company's novel and structurally distinct glucan synthase inhibitor, SCY-078, for the
View HTML